Pharma BD Deal Intelligence
Novavax strikes $1.2 billion deal with Sanofi in major turnaround after pandemic-era decline in COVID vaccine demand.
Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform for COVID-19 and flu-COVID combination vaccine development.
Sanofi paid Novavax $500 million upfront and promised up to $700 million in development, regulatory and launch milestones.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sanofi licensed Novavax's adjuvanted COVID-19 vaccine for exclusive commercialization rights, paying $500M upfront in a deal worth up to $1.2B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Novavax Inc. (this deal) | 2024 | $1.2B | 51 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2024 deals · Sanofi SA deals · Infectious Disease deals